并购战愈演愈烈:辉瑞、诺和诺德百亿美元竞购“减肥药新贵”Metsera

华尔街见闻
Nov 06

为争夺Metsera,辉瑞已迅速跟进,将其收购报价提升至与竞争对手诺和诺德完全相同的水平——总价最高可达100亿美元。此举使这场激烈的竞购战进入白热化阶段。两大巨头争夺的是Metsera在减肥药领域的潜力管线,包括一款月度注射剂,意图在预计规模将达千亿美元的减肥药市场中抢占先机。周一美国市场一日内宣布四笔总额超800亿美元的大型交易,将今年的并购狂潮推向新高。在此背景下,制药巨头辉瑞与诺和诺德对“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10